SynthesisAndrologia2021
Anabolic androgenic steroid-induced hypogonadism, a reversible condition in male individuals? A systematic review.
Synthesis in Andrologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Review
- Non-medical use of exogenous testosterone and anabolic-androgenic substances in young men: health, psychological, and fertility consequences.Frontiers in endocrinology · 2026Review
- Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practice.Harm reduction journal · 2025Article
- Cognitive Behavioral Therapy for Muscle Dysmorphia and Anabolic Steroid-Related Psychopathology: A Randomized Controlled Trial.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data.F&S reports · 2025Article
- Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.Asian journal of andrology · 2025Review
- Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis.Frontiers in chemistry · 2025Article
- Immediate and late effects of supraphysiological doses of nandrolone decanoate on the testis of rats.Acta cirurgica brasileira · 2025Article
- Prolonged post-androgen abuse hypogonadism: potential mechanisms and a proposed standardized diagnosis.Frontiers in endocrinology · 2025Review
- A study of long-term supraphysiologic-dose anabolic-androgenic steroid use on cognitive function in middle-aged men.The American journal of drug and alcohol abuse · 2024Article
- Androgenic-anabolic steroid abuse trend and management: A prospective, cross-sectional, questionnaire-based survey.Health science reports · 2023Article
- Testosterone therapy in children and adolescents: to whom, how, when?International journal of impotence research · 2022Review
- The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.International journal of molecular sciences · 2022Review
- Anabolic-androgenic steroids: How do they work and what are the risks?Frontiers in endocrinology · 2022Review
- Assessment of testicular steroidogenic enzymes expression in experimental animal model following withdrawal of nandrolone decanoate.Journal of animal science and technology · 2021Article
- Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis.Journal of human reproductive sciencesArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anabolic-androgenic steroids (AAS) are clinically used as an androgen replacement, in hypogonadism treatment, to induce puberty, and also in the treatment of chronic degenerative diseases. The AAS use out of clinical context is becoming massively, being used merely for aesthetic reasons. AAS abuse may cause severe disarrangement on the HPG axis and generate a significant decrease in testosterone synthesis and secretion by the testes. This review aims to evaluate whether the hypogonadism induced by AAS abuse is reversible and under what circumstances the reversibility is possible. For this, PRISMA guidelines and several databases are used between July and September 2020. Altogether, this systematic review identified and analysed 179 cases of AAS users. Of these, 168 cases had the hypogonadism clearly diagnosed and proven to be linked exclusively to AAS abuse. However, between these 168 cases, only 38 cases presented fully known outcomes and among these, merely in 4, the hypogonadism was completely reversible (2 based on drug therapy) with HPG axis recovery. In conclusion, this review presents evidences that AAS-induced hypogonadism is a seriously underestimated problem, and in the majority of cases, full recovery is very difficult to succeed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.